ライフサイエンスコーパス: cutaneous T-cell lymphoma

1 ACs), was recently approved for treatment of cutaneous T cell lymphoma.

2 ention of solid tumors and are used to treat cutaneous T cell lymphoma.

3 kines may have added therapeutic benefit for cutaneous T cell lymphoma.

4 CCR4 in the blood and skin of patients with cutaneous T cell lymphoma.

5 often deficient on the malignant T cells of cutaneous T cell lymphoma.

6 ells derived from the blood of patients with cutaneous T cell lymphoma.

7 tors of anti-tumor cell-mediated immunity in cutaneous T cell lymphoma.

8 cells, that resulted in a pattern mimicking cutaneous T cell lymphoma.

9 for Hdac inhibitors that are efficacious in cutaneous T cell lymphoma.

10 developed for the treatment of patients with cutaneous T cell lymphoma.

11 ion for patients with relapsed or refractory cutaneous T-cell lymphoma.

12 is indicated for the treatment of refractory cutaneous T-cell lymphoma.

13 approved for the treatment of patients with cutaneous T-cell lymphoma.

14 Administration approved for the treatment of cutaneous T-cell lymphoma.

15 c T-cell lymphoma and large-cell transformed cutaneous T-cell lymphoma.

16 fungoides (MF) is the most frequent form of cutaneous T-cell lymphoma.

17 llenges in diagnosing and treating pediatric cutaneous T-cell lymphoma.

18 orms, and to recognize its relationship with cutaneous T-cell lymphoma.

19 ministration for vorinostat for treatment of cutaneous T-cell lymphoma.

20 approved for SAHA (vorinostat) treatment of cutaneous T-cell lymphoma.

21 from an international registry of pediatric cutaneous T-cell lymphoma.

22 ses in childhood: pityriasis lichenoides and cutaneous T-cell lymphoma.

23 presentation are characteristic of pediatric cutaneous T-cell lymphoma.

24 es of mycosis fungoides, a common variant of cutaneous T-cell lymphoma.

25 n of EZH2 activity in large-cell transformed cutaneous T-cell lymphoma.

26 a, such as CD30+ Hodgkin's disease and CD30+ cutaneous T-cell lymphoma.

27 estrina with CD8(+) T-cell mycosis fungoides-cutaneous T-cell lymphoma.

28 ells in 3 patients with nodal involvement by cutaneous T-cell lymphoma.

29 pigtailed macaque (Macaca nemestrina) with a cutaneous T-cell lymphoma.

30 atopic and allergic contact dermatitis, and cutaneous T-cell lymphoma.

31 nal antibody, in 41 pretreated patients with cutaneous T-cell lymphoma.

32 S) is an aggressive CD4+ leukemic variant of cutaneous T-cell lymphoma.

33 cancer prodrug approved for the treatment of cutaneous T-cell lymphoma.

34 ons of these agents to treat skin cancer and cutaneous T-cell lymphoma.

35 CpGs have demonstrated efficacy for cutaneous T-cell lymphoma.

36 diated itch, including atopic dermatitis and cutaneous T-cell lymphoma.

37 us cell cancer, lentigo maligna melanoma and cutaneous T-cell lymphoma.

38 of two HDAC inhibitors for the treatment of cutaneous T-cell lymphoma.

39 gets acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma.

40 is fungoides (MF) is the most common primary cutaneous T-cell lymphoma.

41 s, comprises the second most common group of cutaneous T-cell lymphoma.

42 irst HDACi was approved for the treatment of cutaneous T cell lymphomas.

43 re few data on the molecular pathogenesis of cutaneous T cell lymphomas.

44 umulate in the skin, a diagnostic feature of cutaneous T cell lymphomas.

45 ve disease (PCLPD) is a spectrum of indolent cutaneous T-cell lymphomas.

46 eviously treated patients with CD30-positive cutaneous T-cell lymphomas.

47 -delta 1 (TCR delta 1) expression in primary cutaneous T-cell lymphomas.

48 d to evaluate safety and efficacy in CD30(+) cutaneous T-cell lymphomas.

49 unoblastic T-cell lymphoma and other primary cutaneous T-cell lymphomas.

50 gression and may have applicability to human cutaneous T-cell lymphomas.

51 redominant Hodgkin's disease (7 cases), CD4+ cutaneous T-cell lymphomas (6 cases), adult T-cell leuke

52 e peripheral blood and skin of patients with cutaneous T cell lymphoma, a putative malignancy of the

53 Sezary syndrome is an advanced form of cutaneous T-cell lymphoma, a clonally derived malignancy

54 ymphoma, angioimmunoblastic T-cell lymphoma, cutaneous T-cell lymphoma, adult T-cell leukemia/lymphom

55 al role for HTLV-1 in these cases of primary cutaneous T-cell lymphoma after solid organ transplant.

56 otherapy demonstrated activity in refractory cutaneous T-cell lymphomas, along with acceptable toxici

57 thway may play a role in the pathogenesis of cutaneous T-cell lymphomas, although the mechanism (indu

58 f malignant T cells from the skin lesions of cutaneous T cell lymphoma and the isolation of tumor-inf

59 .S. cases per year) that now exceeds that of cutaneous T-cell lymphoma and a mortality (33%) exceedin

60 (HDAC) inhibitors are currently approved for cutaneous T-cell lymphoma and are in mid-late stage tria

61 h2 phenotype in patients with advanced-stage cutaneous T-cell lymphoma and highlight the Gal-1-Gal-1

62 let A radiation, is used clinically to treat cutaneous T-cell lymphoma and immune-mediated diseases s

63 acetylase inhibitor used in the treatment of cutaneous T-cell lymphoma and in clinical trials for tre

64 It is approved for the treatment of cutaneous T-cell lymphoma and is used experimentally for

65 l cell and squamous cell cancers, as well as cutaneous T-cell lymphoma and lentigo maligna melanoma.

66 vedotin is both active and well tolerated in cutaneous T-cell lymphoma and lymphomatoid papulosis, wi

67 fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma and may rarely infiltrate the

68 urvival between the patients with alpha beta cutaneous T-cell lymphoma and patients with gamma delta

69 e deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia.

70 (SAHA), is currently being used for treating cutaneous T-cell lymphoma and under clinical trials for

71 nical trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and LyP from 2011 to 2013.

72 tyrosine kinase Brk in a large proportion of cutaneous T-cell lymphomas and other transformed T- and

73 hat cell-mediated responses are important in cutaneous T cell lymphoma, and that augmentation of thes

74 (SAHA) has been approved as a drug to treat cutaneous T cell lymphoma, and the combination of HDACi

75 nical treatment of several skin diseases and cutaneous T cell lymphoma, and they are also commonly us

76 levels as a tumor classification scheme for cutaneous T cell lymphomas, and have promise in the phar

77 gkin disease patients, non-Hodgkin lymphoma, cutaneous T-cell lymphoma, and acute leukemias.

78 f aberrant cell proliferation in dermatitis, cutaneous T-cell lymphoma, and graft-versus-host disease

79 ed but dramatic response in one patient with cutaneous T-cell lymphoma, and prolongation of progressi

80 nodal peripheral T-cell lymphomas, 1/3 CD8+ cutaneous T-cell lymphomas, and 5/38 classical Hodgkin's

81 pityriasis versicolor, nummular eczema, and cutaneous T-cell lymphoma are important to consider in t

82 Cutaneous T-cell lymphomas are rare, generally incurable

83 Malignant melanoma and mycosis fungoides (cutaneous T cell lymphoma) are rare malignancies in chil

84 tic efficacy of this cytokine in early stage cutaneous T cell lymphoma as compared with more advanced

85 Unlike some B-cell lymphomas, cutaneous T-cell lymphomas as a group are rarely if ever

86 been observed in a number of cases of human cutaneous T cell lymphomas, as well as human B-cell lymp

87 Sezary syndrome (SzS) is an advanced form of cutaneous T-cell lymphoma associated with involvement of

88 s (MF) is the most frequent manifestation of cutaneous T cell lymphoma but its cause and pathophysiol

89 Its efficacy has been shown in CD25+ cutaneous T-cell lymphoma, but not in B-cell non-Hodgkin

90 ve demonstrated efficacy in the treatment of cutaneous T-cell lymphomas, but the mechanism of action

91 kin biopsy specimens of 104 individuals with cutaneous T-cell lymphoma by immunohistochemistry.

92 from 42 patients with the leukemic phase of cutaneous T cell lymphoma (CD4/CD8 ratio of 10 or more w

93 In a cutaneous T-cell lymphoma cell line, promoter hypermethy

94 fects of enzastaurin on the viability of the cutaneous T-cell lymphoma cell lines HuT-78 and HH by us

95 e enhancer region, of the ICOS gene, whereas cutaneous T-cell lymphoma cell lines, which strongly exp

96 Sezary syndrome is a rare leukemic form of cutaneous T cell lymphoma characterized by generalized r

97 ezary syndrome (SS) is the leukemic phase of cutaneous T cell lymphoma characterized by the prolifera

98 Mycosis fungoides (MF) is a cutaneous T-cell lymphoma characterized by multifocal di

99 ome (SS) is an incurable leukemic variant of cutaneous T-cell lymphoma characterized by recurrent chr

100 is an aggressive leukemic variant of primary cutaneous T-cell lymphoma characterized by the presence

101 een associated with the development of human cutaneous T cell lymphomas, chronic lymphocytic leukemia

102 ecular mechanisms by which advanced cases of cutaneous T cell lymphoma (CTCL) (mycosis fungoides/Seza

103 e to identify Vbeta+ cases of leukemic phase cutaneous T cell lymphoma (CTCL) and to compare the perc

104 ape and dynamics of active regulatory DNA in cutaneous T cell lymphoma (CTCL) by ATAC-seq.

105 In this article, we report that cutaneous T cell lymphoma (CTCL) cells and tissues ubiqu

106 Cutaneous T cell lymphoma (CTCL) is a non-Hodgkin lympho

107 We previously showed that within cutaneous T cell lymphoma (CTCL) lesions, malignant CD4(

108 yndrome is a leukemic and aggressive form of cutaneous T cell lymphoma (CTCL) resulting from the mali

109 -10, is a hallmark of the advanced stages of cutaneous T cell lymphoma (CTCL), where it has been asso

110 ved for single-agent treatment of refractory cutaneous T cell lymphoma (CTCL).

111 ant mature CD4(+) T lymphocytes derived from cutaneous T cell lymphomas (CTCL) variably display some

112 is currently in phase II clinical trials for cutaneous T cell lymphomas (CTCL), but the mechanism of

113 st cells in skin biopsies from patients with cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell ly

114 ezary syndrome (SS) is a leukemic variant of cutaneous T-cell lymphoma (CTCL) and represents an ideal

115 Patients with cutaneous T-cell lymphoma (CTCL) are frequently colonize

116 (TL) and telomerase activity (TA) in primary cutaneous T-cell lymphoma (CTCL) by using quantitative p

117 FAS expression was generally low in 30 of 31 cutaneous T-cell lymphoma (CTCL) cases (mycosis fungoide

118 address the antitumor effect of curcumin on cutaneous T-cell lymphoma (CTCL) cell lines and peripher

119 nhibitor (HDI) resistance, we selected HuT78 cutaneous T-cell lymphoma (CTCL) cells with romidepsin i

120 s and Sezary syndrome are two major forms of cutaneous T-cell lymphoma (CTCL) characterized by resist

121 n 20 individuals with well-defined stages of cutaneous T-cell lymphoma (CTCL) comprising 10 cases wit

122 Cutaneous T-cell lymphoma (CTCL) constitutes a malignant

123 Studies in an in vitro model of cutaneous T-cell lymphoma (CTCL) demonstrated that CTCL

124 Cutaneous T-cell lymphoma (CTCL) encompasses leukemic va

125 Patients with advanced cutaneous T-cell lymphoma (CTCL) exhibit profound defect

126 orts in recent years, a curative therapy for cutaneous T-cell lymphoma (CTCL) has not yet been develo

127 y of zanolimumab in patients with refractory cutaneous T-cell lymphoma (CTCL) have been assessed in t

128 ll lines and tissue samples of patients with cutaneous T-cell lymphoma (CTCL) have reported a detecti

129 Cutaneous T-cell lymphoma (CTCL) incidence and survival

130 of HTLV-I genetic sequences in patients with cutaneous T-cell lymphoma (CTCL) including mycosis fungo

131 Systemic treatment for cutaneous T-cell lymphoma (CTCL) involves the use of les

132 Cutaneous T-cell lymphoma (CTCL) is a heterogeneous grou

133 Cutaneous T-cell lymphoma (CTCL) is a heterogeneous grou

134 Cutaneous T-cell lymphoma (CTCL) is a heterogeneous non-

135 Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin

136 Cutaneous T-cell lymphoma (CTCL) is an aggressive neopla

137 Cutaneous T-cell lymphoma (CTCL) is an incurable non-Hod

138 Progression of cutaneous T-cell lymphoma (CTCL) is associated with prof

139 Cutaneous T-cell lymphoma (CTCL) is characterized by pro

140 Cutaneous T-cell lymphoma (CTCL) is characterized by the

141 Cutaneous T-cell lymphoma (CTCL) is defined by infiltrat

142 Cutaneous T-cell lymphoma (CTCL) is typically a skin-inf

143 murine T-cell lymphoma line, MBL2, and human cutaneous T-cell lymphoma (CTCL) lines, HH and Hut78, we

144 Cutaneous T-cell lymphoma (CTCL) may present with eczema

145 Importance: Cutaneous T-cell lymphoma (CTCL) of the hands and feet c

146 Sezary syndrome (SS) is an aggressive cutaneous T-cell lymphoma (CTCL) of unknown etiology in

147 ropositivity increases with age, a subset of cutaneous T-cell lymphoma (CTCL) patients 55 years or yo

148 eripheral blood involvement in patients with cutaneous T-cell lymphoma (CTCL) portend a worse clinica

149 Advanced cutaneous T-cell lymphoma (CTCL) remains an unmet medica

150 ies, compared to six healthy control and six cutaneous T-cell lymphoma (CTCL) samples from previously

151 T-cell lines established from patients with cutaneous T-cell lymphoma (CTCL) spontaneously secrete I

152 ing cells and because malignant cells of the cutaneous T-cell lymphoma (CTCL) subset, Sezary syndrome

153 mycosis fungoides or Sezary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes.

154 Previous cytogenetic studies of primary cutaneous T-cell lymphoma (CTCL) were based on limited n

155 Diego, CA]) in patients with stage Ib to IVa cutaneous T-cell lymphoma (CTCL) who have previously rec

156 is fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL), a heterogeneous group

157 mpound 1 has FDA approval as a treatment for cutaneous T-cell lymphoma (CTCL), although treatment wit

158 roRNA (miRNA) dysregulation is a hallmark of cutaneous T-cell lymphoma (CTCL), an often-fatal maligna

159 n mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), as compared to normal

160 The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sezary syndr

161 ts with stage IA to III, CD25 assay-positive cutaneous T-cell lymphoma (CTCL), including the mycosis

162 s of mycosis fungoides (MF), the most common cutaneous T-cell lymphoma (CTCL), is unknown.

163 In early-stage cutaneous T-cell lymphoma (CTCL), malignant T cells are

164 The pathogenesis of the cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF)

165 initial cohort was limited to patients with cutaneous T-cell lymphoma (CTCL), or subtypes mycosis fu

166 nction and histologically confirmed relapsed cutaneous T-cell lymphoma (CTCL), other non-Hodgkin's ly

167 immunotherapy on the natural progression of cutaneous T-cell lymphoma (CTCL), particularly the mycos

168 In the initial stage of cutaneous T-cell lymphoma (CTCL), proliferating CTCL cel

169 depsin in patients with treatment refractory cutaneous T-cell lymphoma (CTCL).

170 cell transplantation (HSCT) in patients with cutaneous T-cell lymphoma (CTCL).

171 vanced mycosis fungoides and Sezary syndrome cutaneous T-cell lymphoma (CTCL).

172 ave shown clinical efficacy against advanced cutaneous T-cell lymphoma (CTCL).

173 tional properties of cells derived from CD4+ cutaneous T-cell lymphoma (CTCL).

174 in malignant CD4(+) T cells derived from the cutaneous T-cell lymphoma (CTCL).

175 Group classification and staging system for cutaneous T-cell lymphoma (CTCL).

176 ) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL).

177 (SS), the erythrodermic and leukemic form of cutaneous T-cell lymphoma (CTCL).

178 ber of hematological malignancies, including cutaneous T-cell lymphoma (CTCL).

179 lase inhibitor approved for the treatment of cutaneous T-cell lymphoma (CTCL).

180 e lesional skin of 42 American patients with cutaneous T-cell lymphoma (CTCL).

181 vival, proliferation, and tumor formation in cutaneous T-cell lymphoma (CTCL).

182 miR-150) repression in an aggressive form of cutaneous T-cell lymphoma (CTCL).

183 ttle is known about their pathogenic role in cutaneous T-cell lymphoma (CTCL).

184 diagnosis and for monitoring progression of cutaneous T-cell lymphoma (CTCL)/SS and that FCRL3 expre

185 Compound 1 is FDA-approved for treatment of cutaneous T-cell lymphoma (CTCL); however, 1 can provoke

186 Compound 1 has FDA approval to treat cutaneous T-cell lymphoma (CTCL); however, its use can c

187 Cutaneous T-cell lymphomas (CTCL) represent a spectrum o

188 tigate the anti-tumor effects of avicin D in cutaneous T-cell lymphomas (CTCL), we compared three CTC

189 (Targretin) is widely used for treatment of cutaneous T-cell lymphomas (CTCL).

190 es of CCND1 and its regulator RB1 in primary cutaneous T-cell lymphomas (CTCL).

191 Cutaneous T cell lymphomas (CTCLs) are a heterogenous gr

192 Cutaneous T cell lymphomas (CTCLs) represent a heterogen

193 and Sezary syndrome comprise the majority of cutaneous T cell lymphomas (CTCLs), disorders notable fo

194 Cutaneous T-cell lymphomas (CTCLs) accounted for 71% (ag

195 Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous g

196 Cutaneous T-cell lymphomas (CTCLs) are a heterogenous gr

197 Cutaneous T-cell lymphomas (CTCLs) are malignancies of T

198 Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin's lym

199 Primary cutaneous T-cell lymphomas (CTCLs) encompass a wide vari

200 Cutaneous T-cell lymphomas (CTCLs) form a heterogeneous

201 Cutaneous T-cell lymphomas (CTCLs) primarily affect skin

202 Cutaneous T-cell lymphomas (CTCLs) represent a group of

203 n diftitox was approved for the treatment of cutaneous T-cell lymphomas (CTCLs) with CD25+ expression

204 ly driven diseases, the malignant T cells of cutaneous T-cell lymphomas (CTCLs), such as Sezary syndr

205 eviously been shown to be hypermethylated in cutaneous T-cell lymphomas (CTCLs), using standard bisul

206 common but aggressive subset of CD8(+) human cutaneous T-cell lymphomas (CTCLs).

207 Sezary syndrome, are the most common primary cutaneous T-cell lymphomas (CTCLs).

208 likely to be most effective for early stage cutaneous T cell lymphoma due to a greater display of be

209 thyroxine concentrations) in a patient with cutaneous T-cell lymphoma during therapy with the retino

210 In a model of cutaneous T cell lymphoma, epidermotropic CD4(+) TRM lym

211 Two patients with cutaneous T-cell lymphoma experienced major antitumor re

212 er the neoplastic T cells from patients with cutaneous T-cell lymphoma express tumor-specific antigen

213 blood of a patient with an indolent form of cutaneous T-cell lymphoma, express wild-type TbetaRII an

214 eterogenous immune-mediated diseases such as cutaneous T cell lymphoma, graft-versus-host disease, an

215 tochemotherapy (ECP) is widely used to treat cutaneous T-cell lymphoma, graft-versus-host disease, an

216 e National Cancer Institute, 3 patients with cutaneous T-cell lymphoma had a partial response, and 1

217 Four patients with advanced cutaneous T-cell lymphoma had CD8 cells that specificall

218 cell receptor junctional region sequences in cutaneous T-cell lymphoma had not been previously report

219 ls with recombinant human interleukin-12 for cutaneous T cell lymphoma have demonstrated that it is a

220 and Sezary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics t

221 l cancer kindred and a panel we designed for cutaneous T cell lymphoma in order to compare detection

222 Forty-two patients with cutaneous T-cell lymphoma, including 31 with exfoliative

223 CXCR4, and CCR10, in the pathophysiology of cutaneous T-cell lymphoma, including mycosis fungoides a

224 cles on pityriasis lichenoides and pediatric cutaneous T-cell lymphoma, including recent findings fro

225 Among the novel therapies for cutaneous T-cell lymphoma, interleukin-2 fusion toxins,

226 Cutaneous T cell lymphoma is a clonally derived, skin-in

227 Cutaneous T-cell lymphoma is a heterogeneous group of ly

228 Cutaneous T-cell lymphoma is a rare but underrecognized

229 Cutaneous T-cell lymphoma is the overall name for a grou

230 e Sezary form, or typically leukemic form of cutaneous T cell lymphoma, is characterized by prominent

231 ne receptors by tumors, specifically CCR4 on cutaneous T cell lymphomas, is often associated with a p

232 zary syndrome (SzS), the leukemic variant of cutaneous T-cell lymphomas, is incurable.

233 hydroxamic acid is already approved to treat cutaneous T-cell lymphoma, it could potentially be used

234 report, we show that patients with leukemic cutaneous T-cell lymphomas, known to have limited comple

235 A and CCR4 were also found at high levels in cutaneous T cell lymphoma lesions along with abundant ex

236 toxin efficiently eradicated CCR4-expressing cutaneous T cell lymphoma/leukemia established in NOD-SC

237 ed 17 adults with stage IA through stage IIA cutaneous T-cell lymphoma, MF type, to evaluate treatmen

238 onsiveness was assessed in 276 patients with cutaneous T cell lymphoma (mycosis fungoides and Sezary

239 ith early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type,

240 Although most patients with the cutaneous T-cell lymphoma, mycosis fungoides (MF), are s

241 an extended survival, and the development of cutaneous T cell lymphomas of CD8(+)CD4(-) phenotype.

242 Seven partial responses were observed in cutaneous T-cell lymphoma (one patient), HCL (three pati

243 administered to 28 patients who had relapsed cutaneous T-cell lymphoma or peripheral T-cell lymphoma

244 -cell lymphoma and patients with gamma delta cutaneous T-cell lymphoma (P <.0001).

245 sis colorectal cancer panel and 22% with the cutaneous T cell lymphoma panel.

246 e signaling pathway previously implicated in cutaneous T-cell lymphoma pathogenesis, JAK/STAT signali

247 The addition of interleukin-12 to cutaneous T cell lymphoma patient peripheral blood cells

248 both the natural killer cell activity of 15 cutaneous T cell lymphoma patients as well as T cell sur

249 ntly, studies of acute myeloid leukaemia and cutaneous T cell lymphoma patients have revealed importa

250 In the blood of cutaneous T cell lymphoma patients with peripheral blood

251 rleukin-12 receptor expression by T cells of cutaneous T cell lymphoma patients.

252 udies addressing the therapeutic efficacy in cutaneous T-cell lymphoma patients.

253 vestigation of mogamulizumab is warranted in cutaneous T-cell lymphoma patients.

254 tion of malignant T cells from patients with cutaneous T cell lymphoma, PBMC from normal individuals,

255 to isolate and characterize tumor-associated cutaneous T-cell lymphoma peptides.

256 r cells from patients with leukemic forms of cutaneous T cell lymphoma, primarily Sezary syndrome (SS

257 thological findings of the leukemic phase of cutaneous T-cell lymphoma, primarily Sezary syndrome (SS

258 Cutaneous T-cell lymphomas represent clinically and biol

259 ) was more frequent than CDKN2A (12%) in all cutaneous T-cell lymphoma stages using quantitative reve

260 The specific role of MTAP in cutaneous T-cell lymphoma subgroups, mycosis fungoides (

261 e near complete apoptosis (94%) in malignant cutaneous T cell lymphoma T cells, whereas lower levels

262 HL) 1.42 (1.00, 2.02) and 3.18 (1.01, 9.97); cutaneous T-cell lymphoma (TCL) 4.10 (2.70, 6.23) and 10

263 genetic remissions in patients with advanced cutaneous T-cell lymphoma that is refractory to standard

264 of T cell lymphomas and all (eight of eight) cutaneous T-cell lymphoma tissues with a transformed, la

265 distinctive class I associated molecules on cutaneous T-cell lymphoma tumor cells suggests that infi

266 is fungoides (MF) is the most common primary cutaneous T-cell lymphoma variant and is closely related

267 In 2 of 3 organ recipients, a cutaneous T-cell lymphoma was diagnosed 2 and 3 years af

268 d Sezary syndrome are the most common of the cutaneous T-cell lymphomas, which are a heterogeneous gr

269 Hypothyroidism may develop in patients with cutaneous T-cell lymphoma who are treated with high-dose

270 aluated thyroid function in 27 patients with cutaneous T-cell lymphoma who were enrolled in trials of

271 ated 14 patients with relapsed or refractory cutaneous T-cell lymphoma with escalating doses of bexar

272 group of patients with refractory, advanced, cutaneous T-cell lymphoma with evidence for graft-versus

273 s and treatment approaches for patients with cutaneous T-cell lymphoma with special emphasis on mycos

274 ribe the chromatin accessibility profiles of cutaneous T cell lymphoma, with dynamic assessments of r